12:00 AM
Oct 29, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Oxtellar XR oxcarbazepine regulatory update

Supernus said FDA approved an NDA for Oxtellar XR oxcarbazepine as an adjunctive therapy for epilepsy in adults and children ages 6-17 years old. The company plans to launch the oral, once-daily extended-release...

Read the full 144 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >